Analysis of retinal nerve layers in idiopathic, LRRK2-associated Parkinson's disease and unaffected carriers of G2019S mutation

Parkinsonism Relat Disord. 2023 Jan:106:105246. doi: 10.1016/j.parkreldis.2022.105246. Epub 2022 Dec 14.

Abstract

Introduction: In both prodromal and early symptomatic stages of idiopathic PD (iPD) peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell layer (mGCL) thinning have been identified. Here we assessed whether these alterations can also be detected in symptomatic and presymptomatic stages of LRRK2-PD.

Methods: 218 eyes belonging to 20 iPD, 19 LRRK2-PD (L2PD), 24 LRRK2 non-manifesting carriers (L2NMC), and 46 controls (HCs). pRNFL, mGCL thickness (squares), and Bruch's membrane opening minimum rim width were evaluated by SD-OCT. In L2NMC, 123I-ioflupane SPECT (DaT-SPECT) with semi-quantitative analysis was carried out.

Results: Compared to HCs, iPD patients showed significant thinning of the temporal (BMO-MRW and pRNFL), superior-temporal (BMO-MRW), inferior-temporal (BMO-MRW), superior-nasal (BMO-MRW) and central sectors (BMO-MRW) (p < 0.05), as well as in five mGCL sectors (p < 0.05). No significant differences were found between the L2PD or L2NMC and HCs. BMO-MRW thickness in its temporal-superior, superior-nasal and middle sectors was influenced by disease duration (p < 0.05) and mGCL thickness in sectors TS1, TS2, TS3, NS1 and NS3 was influenced by UPDRSIII and age (p < 0.05).

Conclusion: LRRK2-PD is distinguished from iPD by absent or less retinal nerve involvement, both in clinical and preclinical stages.

Keywords: (123)I-ioflupane; Biomarker; LRRK2; Optical coherence tomography; Parkinson's disease; Retina.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Intraocular Pressure
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
  • Nerve Fibers
  • Optic Disk*
  • Parkinson Disease* / diagnostic imaging
  • Parkinson Disease* / genetics
  • Retinal Ganglion Cells
  • Tomography, Optical Coherence / methods

Substances

  • LRRK2 protein, human
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2